Nash P, Behrens F, Orbai A, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open 2018;4:e000692. doi: 10.1136/ rmdopen-2018-000692 This article has been corrected since it first published. There were some copyediting errors which have been rectified now.
ASJC Scopus subject areas
- Immunology and Allergy